Antares Pharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Antares Pharma, Inc. operates as a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products and technologies using proprietary drug delivery systems, particularly self-injection platforms for therapeutic areas including endocrinology, urology, rheumatology, and neurology. The company offers XYOSTED (testosterone enanthate) injection for testosterone replacement therapy; OTREXUP (methotrexate) injection for rheumatoid arthritis; NOCDURNA (desmopressin acetate) sublingual tablets for nocturia; and devices such as QuickShot auto-injectors, disposable pen injectors, and subcutaneous auto-injectors like Makena and epinephrine injection USP; it also provides sumatriptan injection USP and teriparatide injection for osteoporosis. Founded in 1979 and headquartered in Ewing, New Jersey, with prior facilities in Minnesota, Antares Pharma conducts operations primarily in the United States through its drug/device combination products targeting adult males with hypogonadism, patients with autoimmune conditions, and those requiring emergency injectables. In 2022, Halozyme Therapeutics acquired Antares Pharma for approximately $960 million at $5.60 per share, integrating its auto-injector platform into Halozyme's portfolio to enhance drug delivery capabilities and diversify revenue streams; the deal closed following HSR Act clearance and proved immediately accretive to Halozyme's earnings. Halozyme now positions Antares Pharma products under its umbrella, emphasizing patient-centric innovations in self-administration while leveraging ongoing partnerships originally held by Antares with entities such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals for injector-based therapies.
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?
Antares Pharma Inc shares up 45% on Wednesday: how come?
Why Antares Pharma Stock Is Soaring Today
Why Is Antares Pharma (ATRS) Stock Up Today?
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Why Antares Pharma Stock Is Bolting Higher Today
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium
Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
A Look At Recent Moves By Antares Pharma
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript
Antares Pharma (ATRS) Reports Next Week: What to Expect
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying